Kohei Shitara, MD, discusses first-line nivolumab plus chemotherapy vs chemotherapy alone in gastric cancer, GEJ cancer, or esophageal adenocarcinoma.
Kohei Shitara, MD, National Cancer Center Hospital East, Japan
Advertisement
Articles by Kohei Shitara, MD, National Cancer Center Hospital East, Japan
Advertisement
Latest Updated Articles
Dr Shitara on the 4-Year Outcomes of the CheckMate 649 Trial in GEJ AdenocarcinomaPublished: January 20th 2024 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
4
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
5